Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The heme detoxification pathway in Plasmodium falciparum is a vital metabolic process that allows the malaria parasite to survive while consuming host hemoglobin within red blood cells (Sullivan, 2002, PMID: 12456505). During the intraerythrocytic stage, the parasite digests up to 80% of host hemoglobin to acquire amino acids, a process that releases toxic free heme, specifically ferriprotoporphyrin IX (FPIX) (Egan, 2008, PMID: 18312134). Because free heme can cause oxidative damage and membrane lysis, the parasite detoxifies it by sequestering it into an insoluble, non-toxic crystalline form called hemozoin, or malaria pigment (Hempelmann, 2007, PMID: 17343618). This biocrystallization occurs in the acidic food vacuole and is mediated by the heme detoxification protein (HDP) and potentially other factors like histidine-rich proteins (Jani et al., 2008, PMID: 18430894). This pathway is the primary target for several classes of antimalarial drugs, most notably the quinolines like chloroquine and quinine, which bind to heme and inhibit its crystallization (Combrinck et al., 2013, PMID: 23317562). The resulting buildup of toxic heme-drug complexes leads to parasite death, though the emergence of resistance via transporters like PfCRT remains a significant clinical challenge.
Inhibition of heme biocrystallization into hemozoin, leading to the accumulation of toxic free heme (ferriprotoporphyrin IX) which causes parasite death via membrane damage and oxidative stress (Combrinck et al., 2013, PMID: 23317562).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heme detoxification pathway (Plasmodium falciparum) (HDP).